ABUS
Arbutus Biopharma Corp

16,836
Mkt Cap
$830.84M
Volume
894,067.00
52W High
$5.10
52W Low
$2.71
PE Ratio
-19.48
ABUS Fundamentals
Price
$4.41
Prev Close
$4.32
Open
$4.30
50D MA
$4.45
Beta
0.91
Avg. Volume
955,309.91
EPS (Annual)
-$0.3767
P/B
10.71
Rev/Employee
$140,250.00
Loading...
Loading...
News
all
press releases
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Arbutus Biopharma (NASDAQ:ABUS) Downgraded by Wall Street Zen to Hold
Wall Street Zen cut Arbutus Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
Arbutus Biopharma (NASDAQ:ABUS) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus...
MarketBeat·12d ago
News Placeholder
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks·7mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks·7mo ago

Latest ABUS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.